Immunome (NasdaqCM:IMNM) - Share price, News & Analysis

IMNM fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

IMNM Stock Overview

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease.

Rewards

Revenue is forecast to grow 129.42% per year

Risk Analysis

Earnings are forecast to decline by an average of 45.5% per year for the next 3 years

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

Immunome Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immunome
Historical stock prices
Current Share Price	US$2.24
52 Week High	US$27.80
52 Week Low	US$2.09
Beta	0
1 Month Change	-56.51%
3 Month Change	-70.72%
1 Year Change	-87.65%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-83.35%

Recent News & Updates

Feb 21

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

	IMNM	US Biotechs	US Market
7D	-27.7%	0.1%	-2.5%
1Y	-87.7%	-21.7%	-10.4%

Return vs Industry: IMNM underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: IMNM underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is IMNM's price volatile compared to industry and market?
IMNM volatility
IMNM Average Weekly Movement	20.8%
Biotechs Industry Average Movement	12.3%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	2.8%

Stable Share Price: IMNM is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: IMNM's weekly volatility has increased from 15% to 21% over the past year.

About the Company

Founded	Employees	CEO	Website
2006	39	Purnanand Sarma	https://immunome.com

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company’s lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

Immunome Fundamentals Summary

How do Immunome's earnings and revenue compare to its market cap?
IMNM fundamental statistics
Market Cap	US$27.17m
Earnings (TTM)	-US$32.47m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Is IMNM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMNM income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$32.47m
Earnings	-US$32.47m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.68
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did IMNM perform over the long term?

See historical performance and comparison

Valuation

Is Immunome undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

0.72x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMNM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMNM's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: IMNM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IMNM is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMNM's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: IMNM is good value based on its PB Ratio (0.7x) compared to the US Biotechs industry average (1.4x).

Future Growth

How is Immunome forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-45.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMNM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMNM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMNM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMNM's revenue (129.4% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: IMNM's revenue (129.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IMNM's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Immunome performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-40.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IMNM is currently unprofitable.

Growing Profit Margin: IMNM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: IMNM is unprofitable, and losses have increased over the past 5 years at a rate of 40.5% per year.

Accelerating Growth: Unable to compare IMNM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMNM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: IMNM has a negative Return on Equity (-85.72%), as it is currently unprofitable.

Financial Health

How is Immunome's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IMNM's short term assets ($46.3M) exceed its short term liabilities ($9.7M).

Long Term Liabilities: IMNM's short term assets ($46.3M) exceed its long term liabilities ($147.0K).

Debt to Equity History and Analysis

Debt Level: IMNM is debt free.

Reducing Debt: IMNM had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMNM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMNM has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 32.9% each year.

Dividend

What is Immunome current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMNM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMNM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMNM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMNM's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IMNM has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure

CEO

Purnanand Sarma (56 yo)

2.92yrs

Tenure

US$2,112,848

Compensation

Dr. Purnanand Duddu Sarma, Ph D., has been the President and Chief Executive Officer of Immunome, Inc. since June 24, 2019 and its Director since June 2019. Dr. Sarma serves as Director of Vaxess Technolog...

CEO Compensation Analysis

Compensation vs Market: Purnanand's total compensation ($USD2.11M) is above average for companies of similar size in the US market ($USD770.21K).

Compensation vs Earnings: Purnanand's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: IMNM's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Experienced Board: IMNM's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/15 00:00
End of Day Share Price	2022/05/13 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31